Annual Drug Patent Expirations for BREVIBLOC
Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for BREVIBLOC.
The generic ingredient in BREVIBLOC is esmolol hydrochloride. Three suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
